Literature DB >> 11859975

The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.

J F Reavey-Cantwell1, R I Haroun, M Zahurak, R E Clatterbuck, R J Parker, R Mehta, J P Fruehauf, H Brem.   

Abstract

Although several studies have examined brain tumor markers for prognostic value, few investigations have stratified analysis based on specific histologic grade. The objective of this study was to evaluate a single histologic grade of glioma, the grade IV glioma or glioblastoma (World Health Organization Classification), with a comprehensive panel of tumor markers in an attempt to identify those with prognostic significance. Tumor samples from a cohort of patients with glioblastoma multiforme (n = 32) were examined for tumor markers, DNA analysis, and clinical variables in an attempt to determine a 'profile' for this tumor. We used univariate and multivariate statistical analysis to determine the prognostic value of tumor cell ploidy, percent S-phase, DNA index, p53, and Ki-67 labeling index, as well as the variables of gender, race, age, location of tumor, history of chemotherapy, and primary versus recurrent tumor. Two additional tumor markers, multidrug resistance gene 1 and glutathione-S-transferase subtype pi, were included in the sample testing, but were not analyzed statistically. Univariate analysis indicated that increasing age had a strong association with decreased survival. Female gender, increasing Ki-67, no chemotherapy before sample collection, and primary glioblastoma showed some association with decreased survival in the univariate model. The univariate results indicated that race, side of tumor, ploidy, S-phase, DNA index, and p53 had no prognostic value. Multivariate modeling demonstrated that age, gender, and Ki-67 were the strongest factors associated with survival. The relevant literature is reviewed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11859975     DOI: 10.1023/a:1013845004294

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  43 in total

Review 1.  Ki-67 staining as a means to simplify analysis of tumor cell proliferation.

Authors:  C L Hitchcock
Journal:  Am J Clin Pathol       Date:  1991-10       Impact factor: 2.493

Review 2.  p53 and the CNS: tumors and developmental abnormalities.

Authors:  G Fulci; E G Van Meir
Journal:  Mol Neurobiol       Date:  1999-02       Impact factor: 5.590

3.  Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme.

Authors:  M Marutani; H Tonoki; M Tada; M Takahashi; H Kashiwazaki; Y Hida; J Hamada; M Asaka; T Moriuchi
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

Review 4.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

5.  Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas.

Authors:  C Bouvier-Labit; O Chinot; C Ochi; D Gambarelli; H Dufour; D Figarella-Branger
Journal:  Neuropathol Appl Neurobiol       Date:  1998-10       Impact factor: 8.090

6.  Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes.

Authors:  E W Newcomb; H Cohen; S R Lee; S K Bhalla; J Bloom; R L Hayes; D C Miller
Journal:  Brain Pathol       Date:  1998-10       Impact factor: 6.508

7.  Glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma.

Authors:  R Grant; J W Ironside
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

8.  Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

Authors:  W J Curran; C B Scott; J Horton; J S Nelson; A S Weinstein; A J Fischbach; C H Chang; M Rotman; S O Asbell; R E Krisch
Journal:  J Natl Cancer Inst       Date:  1993-05-05       Impact factor: 13.506

9.  The proliferation rate of intracranial tumors as defined by the monoclonal antibody KI 67. Application of the method to paraffin embedded specimens.

Authors:  D K Böker; H J Stark
Journal:  Neurosurg Rev       Date:  1988       Impact factor: 3.042

10.  Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67.

Authors:  P Zuber; M F Hamou; N de Tribolet
Journal:  Neurosurgery       Date:  1988-02       Impact factor: 4.654

View more
  26 in total

1.  CD133+ niches and single cells in glioblastoma have different phenotypes.

Authors:  Karina Christensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  J Neurooncol       Date:  2010-12-24       Impact factor: 4.130

2.  Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma.

Authors:  Andrea Pirzkall; Colleen McGue; Suja Saraswathy; Soonmee Cha; Raymond Liu; Scott Vandenberg; Kathleen R Lamborn; Mitchel S Berger; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2009-12       Impact factor: 12.300

3.  Personalized medicine in neuro-oncology.

Authors:  Victor A Levin
Journal:  CNS Oncol       Date:  2016-03-21

4.  A phase II study of radiotherapy after hyperbaric oxygenation combined with interferon-beta and nimustine hydrochloride to treat supratentorial malignant gliomas.

Authors:  Takaaki Beppu; Katsura Kamada; Ryuji Nakamura; Hiroshi Oikawa; Masaru Takeda; Takeshi Fukuda; Hiroshi Arai; Kuniaki Ogasawara; Akira Ogawa
Journal:  J Neurooncol       Date:  2003-01       Impact factor: 4.130

Review 5.  The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.

Authors:  Anne Linn Johannessen; Sverre Helge Torp
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

6.  Increased tryptophan uptake on PET has strong independent prognostic value in patients with a previously treated high-grade glioma.

Authors:  David O Kamson; Sandeep Mittal; Natasha L Robinette; Otto Muzik; William J Kupsky; Geoffrey R Barger; Csaba Juhász
Journal:  Neuro Oncol       Date:  2014-03-26       Impact factor: 12.300

7.  Protein Analysis of Glioblastoma Primary and Posttreatment Pairs Suggests a Mesenchymal Shift at Recurrence.

Authors:  Matthew D Wood; Gerald F Reis; David E Reuss; Joanna J Phillips
Journal:  J Neuropathol Exp Neurol       Date:  2016-08-18       Impact factor: 3.685

8.  Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas.

Authors:  Michelle S Bradbury; Dolores Hambardzumyan; Pat B Zanzonico; Jazmin Schwartz; Shangde Cai; Eva M Burnazi; Valerie Longo; Steven M Larson; Eric C Holland
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

9.  The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients.

Authors:  Yuya Yoshida; Mitsutoshi Nakada; Tomoya Harada; Shingo Tanaka; Takuya Furuta; Yasuhiko Hayashi; Daisuke Kita; Naoyuki Uchiyama; Yutaka Hayashi; Jun-ichiro Hamada
Journal:  J Neurooncol       Date:  2009-11-25       Impact factor: 4.130

10.  Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Authors:  Rodney N Wiltshire; James E Herndon; Annie Lloyd; Henry S Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.